Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21 Jun '21 Mar '21 Dec '20
Net Income
-83.23-25.72-23.48-52.31-15.99-91.21-10.33-3.21-9.11-13.623.01-17.1614.98-13.12-18.28-16.8-18.0810.71-18.29-21.63
Depreciation & Amortization
0.030.030.050.060.060.060.060.040.030.030.030.030.040.040.040.040.050.050.060.07
Stock-Based Compensation
3.172.961.741.660.750.70.80.830.80.80.640.670.840.681.341.360.90.870.880.85
Other Adjustments
0.16-3.56-5.090.310.32.260.220.290.27-0.060.74-1.592.050.270.26-2.090.250.220.210.77
Change in Receivables
-0-0.17-0.010.654.668.97-13.072.3120.64-20.29-0.79-0.213.95-3.43-1.48-0.72-3.1511.16-11.18
Changes in Inventories
-----7.27-1.17-3.2-0.51-2.39----------
Changes in Accounts Payable
63.56-12.597.785.423.16-4.73-4.852.683.33-0.323.19-1.33-0.55-1.140.66-0.281.03-1.59-0.254.33
Changes in Accrued Expenses
1.02-1.11-2.8-0.231.633.313.273.992.13-0.561.184.822.630.63-1.951.080.52-1.961.450.92
Changes in Unearned Revenue
----0.01-0.01-26.2-3.13-1.84-1.34-2.650.04-4.679.57-1.41-0.842.051.760.772.7511.92
Changes in Other Operating Activities
-25.32-0.73-0.1415.68-27.250.11-0.470.770.470.970.56-0.980.61-1.73-1.41.222.33-2.490.242.83
Operating Cash Flow
-40.62-40.96-21.95-29.41-36.7-103.78-6.64-12.72-1.632.82-10.9-2127.97-11.84-23.61-14.91-11.973.44-1.79-11.13
Capital Expenditures
----0.05-0.11-0.01-0.02-0.18-0.13-0.11-0.09-0.01-0.01-0.02-0.08-0.01-0.01-0.02-0.01-0.03
Sale of Property, Plant & Equipment
-0.090.19-----------------
Purchases of Investments
-176.47-------------------
Investing Cash Flow
-176.470.090.19-0.05-0.11-0.01-0.02-0.18-0.13-0.11-0.09-0.01-0.01-0.02-0.08-0.01-0.01-0.02-0.01-0.03
Long-Term Debt Repaid
------------0.19-0.37-1.11-1.11-1.11-1.11-1.11-1.11-1.11
Net Long-Term Debt Issued (Repaid)
------------0.19-0.37-1.11-1.11-1.11-1.11-1.11-1.11-1.11
Issuance of Common Stock
0.3383.250.1398.28-0.08239.2-0.010-0.2526.240.661.20.250.537.9918.5828.761.52
Repurchase of Common Stock
0.05-0.05----0.02-0.04-------------
Net Common Stock Issued (Repurchased)
0.35383.20.1398.28-0.08239.18-0.040.010-0.2526.240.661.20.250.537.9918.5828.761.52
Other Financing Activities
-0.190.19-0.05-0.08-0.08-0.07-0.05-----0.36-0.72-------
Financing Cash Flow
0.16383.390.0898.21-0.18239.13-0.090.010-0.2626.240.660.11-1.11-0.6136.8821.490.897.650.41
Net Cash Flow
-216.93342.42-21.6968.79-36.98135.35-6.76-12.89-0.242.4515.25-20.3528.07-12.96-24.321.97-12.794.315.84-10.72
Beginning Cash & Cash Equivalents
516.91196.18196.18127.39164.3735.7835.7848.6750.4332.7332.7353.0825.0162.2762.2740.3153.142.9542.9553.67
Ending Cash & Cash Equivalents
299.99516.91174.49196.18127.39164.3729.0235.7848.6750.4347.9832.7353.0825.0137.9762.2740.3153.148.7942.95
Free Cash Flow
-40.62-40.96-21.95-29.47-36.8-103.79-6.67-12.9-1.762.72-10.99-21.0127.96-11.85-23.69-14.91-11.983.42-1.81-11.16
FCF Margin
------34368.05%-685.20%-468.07%-19.10%53.34%-42.10%-205.61%68.63%-190.67%-333.27%-206.41%-169.36%10.42%-74.96%-299.14%
Free Cash Flow Per Share
-1.51-2.63-1.55-3.03-5.64-22.74-1.47-2.85-0.390.60-2.17-5.846.31-3.43-6.95-4.63-4.841.15-0.77-5.05
Levered Free Cash Flow
-43.94-40.12-18.6-31.44-38.5-111.41-16.65-0.95-5.13-18.667.92-15.9326.89-17.86-22.97-13.82-13.534.37-15.17-2.71
Unlevered Free Cash Flow
-49.34-41.79-20.39-33.32-39.91-116.18-14.86-6.45-0.45-11.837.69-15.9127.2-16.74-21.84-12.67-12.375.54-13.99-1.51
SEC Filings: 10-K · 10-Q